Drägerwerk AG & Co. KGaA stock (DE0005550636): TecDAX name advances after recent gains and valuation focus

Drägerwerk AG & Co. KGaA shares extended their recent advance on Xetra on 05/29/2026, leaving the German TecDAX name trading closer to the upper end of its 52-week range as investors reassess valuation metrics after the latest quarterly results.

Drägerwerk AG & Co. KGaA shares traded higher on Xetra on 05/29/2026, with the German medical and safety technology stock changing hands around the low-90s EUR area and building on recent gains that have brought it closer to its 52-week high, according to intraday data from finanzen.net as of 05/29/2026.

The TecDAX-listed name, which is headquartered in Lübeck in northern Germany, saw its preferred shares quoted at about EUR 92.50 versus a prior close near EUR 89.30, implying a session move of a little more than 3 percent and putting its market capitalization in the region of EUR 1.5 billion, based on finanzen.net price information as of 05/29/2026.

Against this backdrop, the company continues to trade on its home market in the Federal Republic of Germany via the Xetra platform under the ticker DRW3 for the preferred share line, while investors can also access the stock on various regional venues such as Tradegate in euros alongside the primary listing, according to exchange data as of 05/29/2026.

The latest share price action comes after a period in which the company presented updated financial information and guidance as part of its regular reporting cycle and maintained its positioning within the German mid-cap technology and healthcare-related segment, which is closely watched by domestic retail and institutional investors following the TecDAX, according to company investor relations materials and Xetra index compositions as of 05/29/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Drägerwerk
• Sector/industry: Medical and safety technology equipment
• Headquarters/country: Lübeck, Germany
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Medical ventilators, anesthesia workstations, patient monitoring systems, gas detection and personal safety solutions
• Home exchange/listing venue: Xetra (DRW3 preferred share line)
• Trading currency: EUR

Drägerwerk AG & Co. KGaA: core business model

The group focuses on supplying hospitals, emergency services and industrial clients with medical and safety technology products, generating revenue primarily from equipment sales complemented by recurring income from consumables, service contracts and software-linked solutions.

Valuation metrics and multiples for Drägerwerk AG & Co. KGaA

With the share price hovering in the low-90s euros on Xetra on 05/29/2026, and a market capitalization in the ballpark of EUR 1.5 billion for the preferred share line, valuation metrics for Drägerwerk sit within the typical range for mid-sized European medical technology suppliers that combine capital-intensive hardware portfolios with more stable service and consumables revenue streams, according to comparative data from European exchange listings and sector screens as of 05/29/2026.

On that basis, investors often look at ratios such as price-to-earnings, enterprise value-to-EBITDA and dividend yield to contextualize Drägerwerk against peers in Germany and the wider euro area, even though the exact multiples move with each trading session; within the current price region the stock embeds expectations for continued profitability improvements set out in the latest quarterly and full-year reporting, while the modest dividend payout policy and capital expenditure needs for innovation in ventilation, monitoring and safety systems influence how the market prices its equity and debt, based on company reporting and sector surveys as of 05/29/2026.

Conclusion

The current trading session has left Drägerwerk AG & Co. KGaA shares higher on their home market in Germany on 05/29/2026, adding to a constructive price pattern that now sits closer to the upper band of the past year’s range. In parallel, the valuation snapshot at a market capitalization around EUR 1.5 billion positions the stock among mid-cap European medical technology and safety names where investors closely weigh earnings progress, capital allocation and innovation spending when comparing to peers. How the balance between hardware demand, service revenues and investment needs evolves over coming quarters is likely to shape where the company’s key multiples settle within the sector spectrum.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.